These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30277012)

  • 1. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
    Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
    Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRN2 and MITF together impact AXL expression in melanoma.
    Simmons JL; Neuendorf HM; Boyle GM
    Exp Dermatol; 2022 Jan; 31(1):89-93. PubMed ID: 33119145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.
    Berlin I; Denat L; Steunou AL; Puig I; Champeval D; Colombo S; Roberts K; Bonvin E; Bourgeois Y; Davidson I; Delmas V; Nieto L; Goding CR; Larue L
    Mol Cell Biol; 2012 Apr; 32(7):1237-47. PubMed ID: 22290434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRN2 is a non-canonical melanoma tumor-suppressor.
    Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
    Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
    Simmons JL; Pierce CJ; Al-Ejeh F; Boyle GM
    Sci Rep; 2017 Sep; 7(1):10909. PubMed ID: 28883623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Perotti V; Baldassari P; Molla A; Vegetti C; Bersani I; Maurichi A; Santinami M; Anichini A; Mortarini R
    Oncogene; 2016 Jun; 35(22):2862-72. PubMed ID: 26387540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
    Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
    EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.
    Bonvin E; Falletta P; Shaw H; Delmas V; Goding CR
    Mol Cell Biol; 2012 Nov; 32(22):4674-83. PubMed ID: 22988297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
    Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
    Vachtenheim J; Ondrušová L
    Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
    Goodall J; Carreira S; Denat L; Kobi D; Davidson I; Nuciforo P; Sturm RA; Larue L; Goding CR
    Cancer Res; 2008 Oct; 68(19):7788-94. PubMed ID: 18829533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
    Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
    Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
    Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
    J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.
    Gopal YN; Rizos H; Chen G; Deng W; Frederick DT; Cooper ZA; Scolyer RA; Pupo G; Komurov K; Sehgal V; Zhang J; Patel L; Pereira CG; Broom BM; Mills GB; Ram P; Smith PD; Wargo JA; Long GV; Davies MA
    Cancer Res; 2014 Dec; 74(23):7037-47. PubMed ID: 25297634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.